恒瑞医药HRS-6257片临床试验获批

Core Viewpoint - Heng Rui Medicine's subsidiary has received approval from the National Medical Products Administration for clinical trials of HRS-6257 tablets, aimed at treating acute and chronic pain, with no similar drugs approved in the domestic market [1] Company Summary - Heng Rui Medicine announced that its subsidiary, Shanghai Heng Rui Medicine Co., Ltd., has been granted a clinical trial approval notice for HRS-6257 tablets [1] - The drug is intended for the treatment of acute and chronic pain [1] - Currently, there are no approved drugs targeting the same mechanism in the domestic market [1]